Comparison of perioperative bleeding risk between direct oral anticoagulants in transurethral resection of prostate

• Published in: BJU international 2024-12, Vol.134 (S2), p.30-37
• Main Authors: Kuo, Lu Yu, Kuo, Jenny, Silverman, Joshua, Kim, Jason Jae Yeun, Letch, Caitlin, McClintock, Scott
• Format: Article
• Language: English
• Subjects: Administration, Oral; Aged; Aged, 80 and over; anticoagulant; Anticoagulants; Anticoagulants - administration & dosage; Anticoagulants - adverse effects; apixaban; Bleeding; Hematuria; Humans; Hyperplasia; Male; Middle Aged; Morbidity; Original; Postoperative Hemorrhage - chemically induced; Postoperative Hemorrhage - epidemiology; Prostate; Prostatic Hyperplasia - complications; Prostatic Hyperplasia - drug therapy; Prostatic Hyperplasia - surgery; Pyrazoles - administration & dosage; Pyrazoles - adverse effects; Pyridones - administration & dosage; Pyridones - adverse effects; Retrospective Studies; rivaroxaban; Rivaroxaban - administration & dosage; Rivaroxaban - adverse effects; Statistical analysis; Stroke; Thromboembolism; Thromboembolism - epidemiology; Thromboembolism - etiology; Thromboembolism - prevention & control; transurethral prostatectomy; Transurethral Resection of Prostate - adverse effects; TURP; Urological Society of Australia and New Zealand; Warfarin - administration & dosage; Warfarin - adverse effects
• ISSN: 1464-4096; 1464-410X; 1464-410X
• DOI: 10.1111/bju.16478

Objectives To evaluate the perioperative morbidity and mortality associated with direct oral anticoagulants (DOACs) and warfarin for patients receiving transurethral resection of prostate (TURP). Patients and Methods This was a single‐centre, retrospective cohort analysis of patients who underwent TURP for benign prostate hyperplasia from April 2019 to December 2023. The primary objective was to evaluate the perioperative bleeding and thromboembolic risk between anticoagulated (AC) vs no‐AC patients. The secondary objective was to evaluate perioperative bleeding and thromboembolic risk between different formulations of DOACs. Patient demographics, prior treatment, prostate size, baseline bleeding risk, and operative details were collected. Bleeding and thromboembolic‐related morbidity were captured within a 3‐month postoperative period. Perioperative management of AC therapy was recorded, and all patients had their AC therapy withheld. Cohort characteristic between the AC vs no‐AC, and DOAC groups were analysed with two‐sided t‐test, and chi‐square test. Further logistic regression analyses were carried out to identified significant variables between the groups. These significant variables were used for adjustment in inverse probability‐weighted treatment effect analysis to evaluate bleeding risk. Results There were 629 patients in the cohort, and 113 (18%) patients were receiving AC therapy. The AC patients were at 1.6 times statistically significant increased risk of acute bleeding, and 11 times increased risk of prolonged haematuria for >14 days. When compared to apixaban, patients on rivaroxaban conferred a statistically significant increased risk of acute bleeding by 2.21 times. Patients receiving AC therapy had a statistically significant increased risk of stroke in the perioperative setting (no‐AC vs AC: 0.4% vs 2.7%, P = 0.01). Conclusion This is the first study to evaluate risk of bleeding for TURP patients receiving DOACs. The AC patients are more likely to experience haematuria and stroke in the perioperative period despite withholding therapy. Apixaban appears to cause less bleeding‐related complications than rivaroxaban.